New Zealand star defender Rebekah Stott is returning to Brighton and Hove Albion after a two year absence. Diagnosed with Hodgkin’s lymphoma in 2020, she returned to Australia to complete chemotherapy treatment in 2021.
A New Zealand international, Stott rejoins after a stint with Australian club Melbourne City. The defender was only able to play eight matches with the side until she received the terrible news.
Stott found out in late 2020 that she had been diagnosed with Hodgkin’s lymphoma. Thus, she could no longer play football in England. Now in remission for a year, she was able to be part of the Bulleen Lions and Melbourne City set-up.
Trying to fully recover in time for the 2023 FIFA Women’s World Cup, she has documented her journey via Instagram. Broadcasting her journey has helped other individuals with Hodgkin’s lymphoma get through the tough times.
More Football News
- Gomes brace guides Sydney FC to victory in the Derby
- ‘Passion is not a crime’ – Bullpen send loud and clear message
- Grace Wilson is the A-Leagues first openly non-binary player
“The circumstances around Stotty’s departure in 2021 were really difficult for everyone, no one more so than for her,” Brighton head coach Hope Powell said.
“She had only been with us for a short period of time, but was already a popular member of the squad before she headed back to Australia for treatment.
“We were all absolutely delighted and relieved when we found out her treatment had gone well and that she was on the mend.
“Now she’s back to full fitness and wants to have a proper go at the WSL and we are happy to have her back.
“Taking the emotions out of the signing, we know we’re getting a really good player with proven international experience and a knowledge of the league.”
The 29-year old has played across the world for teams in Australia, Germany, Norway, the United States and England. She has represented New Zealand in 84 games and has been a rock at the back of the field. Stoot was even able to score four goals in her time playing in the international side.
Subscribe to our newsletter!